1
|
Buntinx F, Lebeau A, Gillot L, Baudin L, Ndong Penda R, Morfoisse F, Lallemand F, Vottero G, Nizet C, Nizet JL, Blacher S, Noel A. Single and combined impacts of irradiation and surgery on lymphatic vasculature and fibrosis associated to secondary lymphedema. Front Pharmacol 2022; 13:1016138. [PMID: 36330083 PMCID: PMC9622766 DOI: 10.3389/fphar.2022.1016138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 10/03/2022] [Indexed: 11/13/2022] Open
Abstract
Lymphedema (LD) refers to a condition of lymphatic dysfunction associated with excessive fluid accumulation, fibroadipose tissue deposition and swelling. In industrialized countries, LD development mainly results from a local disruption of the lymphatic network by an infection or cancer-related surgery (secondary LD). In the absence of efficient therapy, animal models are needed to decipher the cellular and molecular mechanisms underlying LD and test putative drugs. In this study, we optimized and characterized a murine model of LD that combines an irradiation of the mice hind limb and a radical surgery (lymph node resection associated to lymphatic vessel ligation). We investigated the respective roles of irradiation and surgery in LD formation by comparing their impacts, alone or in combination (with different intervention sequences), on eight different features of the pathology: swelling (paw thickness), indocyanine green (ICG) clearance, lymphatic vasculature remodeling, epidermal and dermal thickening, adipocyte accumulation, inflammatory cell infiltration and collagen deposition. This study supports the importance of radiation prior to surgery to experimentally induce a rapid, severe and sustained tissue remodeling harboring the different hallmarks of LD. We provide the first experimental evidence for an excessive deposition of periostin (POSTN) and tenascin-C (TNC) in LD. Through a computerized method of digital image quantification, we established the spatial map of lymphatic expansion, as well as collagen, POSTN and TNC deposition in papillary and reticular dermis of lymphedematous skins. This mouse model is available to study the patho-physiology of LD and test potential therapeutic targets.
Collapse
Affiliation(s)
- F. Buntinx
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
| | - A. Lebeau
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
| | - L. Gillot
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
| | - L. Baudin
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
| | - R. Ndong Penda
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
| | - F. Morfoisse
- U1297-Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut National de la Santé et de la Recherche Médicale (INSERM), University of Toulouse, Toulouse, France
| | - F. Lallemand
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
- Department of Radiotherapy-Oncology, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Liège, Belgium
| | - G. Vottero
- Department of Plastic and Reconstructive Surgery, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Liège, Belgium
| | - C. Nizet
- Department of Plastic and Reconstructive Surgery, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Liège, Belgium
| | - J. L. Nizet
- Department of Plastic and Reconstructive Surgery, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Liège, Belgium
| | - S. Blacher
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
| | - A. Noel
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège (ULiège), Sart-Tilman, Liège, Belgium
- Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wavre, Belgium
- *Correspondence: A. Noel,
| |
Collapse
|
2
|
Lamande M, Lallemand F, Ben Mustapha S, Coucke PA. [Palliation by radiation is also our business !]. Rev Med Liege 2021; 76:375-379. [PMID: 34080366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Radiotherapy (RT), both with a curative and a palliative intent, is one of the cornerstones of oncological treatments. A variety of symptoms linked to cancer can be relieved with RT (such as pain, bleeding, compression exerted by a tumour lesion…). Very often, palliative RT is proposed when other medical treatments (painkillers, morphine…) are no longer efficient, or the patient does not tolerate them anymore. Palliative RT is an integral part of the global supportive oncological care. Indeed, patients' wishes and prognosis are taken into account in each and every step of the treatment pathway. Every treatment deserves an individualized approach and benefits from the best available techniques.
Collapse
Affiliation(s)
- M Lamande
- Service de Radiothérapie, CHU Liège, Belgique
| | - F Lallemand
- Service de Radiothérapie, CHU Liège, Belgique
| | | | - P A Coucke
- Service de Radiothérapie, CHU Liège, Belgique
| |
Collapse
|
3
|
Khbouz B, Rowart P, Lallemand F, Poma L, Krzesinski J, François J. Rôle de l’irradiation dans le pré-conditionnement ischémique rénal chez la souris. Nephrol Ther 2020. [DOI: 10.1016/j.nephro.2020.07.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Lallemand F, Leroi N, Bahri M, Balteau E, Noël A, Coucke P, Plenevaux A, Martinive P. EP-2331: Tumor microenvironment modifications recorded with IVIM perfusion analysis after radiotherapy. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32640-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Lallemand F, Leroi N, Bahri M, Balteau E, Noël A, Coucke P, Plenevaux A, Martinive P. PO-1036: Brain modifications after stereotactic radiotherapy recorded by Functional MRI. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31346-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Dos Santos ES, Caputo SM, Castera L, Gendrot M, Briaux A, Breault M, Krieger S, Rogan PK, Mucaki EJ, Burke LJ, Bièche I, Houdayer C, Vaur D, Stoppa-Lyonnet D, Brown MA, Lallemand F, Rouleau E. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition. Breast Cancer Res Treat 2017; 168:311-325. [PMID: 29236234 DOI: 10.1007/s10549-017-4602-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Accepted: 11/28/2017] [Indexed: 12/19/2022]
Abstract
PURPOSE The molecular mechanism of breast and/or ovarian cancer susceptibility remains unclear in the majority of patients. While germline mutations in the regulatory non-coding regions of BRCA1 and BRCA2 genes have been described, screening has generally been limited to coding regions. The aim of this study was to evaluate the contribution of BRCA1/2 non-coding variants. METHODS Four BRCA1/2 non-coding regions were screened using high-resolution melting analysis/Sanger sequencing or next-generation sequencing on DNA extracted from index cases with breast and ovarian cancer predisposition (3926 for BRCA1 and 3910 for BRCA2). The impact of a set of variants on BRCA1/2 gene regulation was evaluated by site-directed mutagenesis, transfection, followed by Luciferase gene reporter assay. RESULTS We identified a total of 117 variants and tested twelve BRCA1 and 8 BRCA2 variants mapping to promoter and intronic regions. We highlighted two neighboring BRCA1 promoter variants (c.-130del; c.-125C > T) and one BRCA2 promoter variants (c.-296C > T) inhibiting significantly the promoter activity. In the functional assays, a regulating region within the intron 12 was found with the same enhancing impact as within the intron 2. Furthermore, the variants c.81-3980A > G and c.4186-2022C > T suppress the positive effect of the introns 2 and 12, respectively, on the BRCA1 promoter activity. We also found some variants inducing the promoter activities. CONCLUSION In this study, we highlighted some variants among many, modulating negatively the promoter activity of BRCA1 or 2 and thus having a potential impact on the risk of developing cancer. This selection makes it possible to conduct future validation studies on a limited number of variants.
Collapse
Affiliation(s)
- E Santana Dos Santos
- Department of Oncology, Center for Translational Oncology, Cancer Institute of the State of São Paulo - ICESP, São Paulo, Brazil
- Service de Génétique, Institut Curie, Paris, France
- A.C.Camargo Cancer Center, São Paulo, Brazil
| | - S M Caputo
- Service de Génétique, Institut Curie, Paris, France
| | - L Castera
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de MédecinePersonnalisée, Caen, France
| | - M Gendrot
- Service de Génétique, Institut Curie, Paris, France
| | - A Briaux
- Service de Génétique, Institut Curie, Paris, France
| | - M Breault
- Service de Génétique, Institut Curie, Paris, France
| | - S Krieger
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de MédecinePersonnalisée, Caen, France
| | - P K Rogan
- Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
| | - E J Mucaki
- Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
| | - L J Burke
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
| | - I Bièche
- Service de Génétique, Institut Curie, Paris, France
- Université Paris Descartes, Paris, France
| | - C Houdayer
- Service de Génétique, Institut Curie, Paris, France
- Université Paris Descartes, Paris, France
| | - D Vaur
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de MédecinePersonnalisée, Caen, France
| | - D Stoppa-Lyonnet
- Service de Génétique, Institut Curie, Paris, France
- Université Paris Descartes, Paris, France
| | - M A Brown
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
| | - F Lallemand
- Service de Génétique, Institut Curie, Paris, France.
| | | |
Collapse
|
7
|
Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I. Clinical value of R-spondins in triple-negative and metaplastic breast cancers. Br J Cancer 2017; 116:1595-1603. [PMID: 28472820 PMCID: PMC5518860 DOI: 10.1038/bjc.2017.131] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 04/07/2017] [Accepted: 04/13/2017] [Indexed: 01/08/2023] Open
Abstract
Background: RSPO ligands, activators of the Wnt/β-catenin pathway, are overexpressed in different cancers. The objective of this study was to investigate the role of RSPOs in breast cancer (BC). Methods: Expression of RSPO and markers of various cancer pathways were measured in breast tumours and cell lines by qRT–PCR. The effect of RSPO on the Wnt/β-catenin pathway activity was determined by luciferase assay, western blotting, and qRT–PCR. The effect of RSPO2 inhibition on proliferation was determined by using RSPO2 siRNAs. The effect of IWR-1, an inhibitor of the Wnt/β-catenin pathway, was examined on the growth of an RSPO2-positive patient-derived xenograft (PDX) model of metaplastic triple-negative BC. Results: We detected RSPO2 and RSPO4 overexpression levels in BC, particularly in triple-negative BC (TNBC), metaplastic BC, and triple-negative cell lines. Various mechanisms could account for this overexpression: presence of fusion transcripts involving RSPO, and amplification or hypomethylation of RSPO genes. Patients with RSPO2-overexpressing tumours have a poorer metastasis-free survival (P=3.6 × 10−4). RSPO2 and RSPO4 stimulate Wnt/β-catenin pathway activity. Inhibition of RSPO expression in a TN cell line inhibits cell growth, and IWR-1 significantly inhibits the growth of an RSPO2-overexpressing PDX. Conclusions: RSPO overexpression could therefore be a new prognostic biomarker and therapeutic target for TNBC.
Collapse
Affiliation(s)
- F Coussy
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - F Lallemand
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - S Vacher
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - A Schnitzler
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - W Chemlali
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - M Caly
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - A Nicolas
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - S Richon
- CNRS, UMR 144, Research Center, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - D Meseure
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - R El Botty
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - L De-Plater
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - L Fuhrmann
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - T Dubois
- Breast Cancer Biology Group, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - S Roman-Roman
- Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - V Dangles-Marie
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris 75006, France
| | - E Marangoni
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - I Bièche
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France.,EA7331, University Paris Descartes, 4 avenue de l'observatoire, Paris 75006, France
| |
Collapse
|
8
|
Leroi N, Lallemand F, Leenders J, Blacher S, De Tullio P, Coucke P, Noel A, Martinive P. PO-0985: Tumor metabolic changes after neoadjuvant radiotherapy: consequences for surgery-related metastases. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31421-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Lallemand F, Leroi N, Bahri M, Balteau E, Noel A, Coucke P, Martinive P, Plenevaux A. EP-2049: Diffusion MRI for following tumor modifications after neoadjuvant radiotherapy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33300-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Vandaele R, Marée R, Coucke P, Lenaerts E, Gulyban A, Lallemand F, Geurts P, Jodogne S, Martinive P. EP-1529: Automated landmarks detection for rigid registration between the simulation-CT and the treatment CBCT. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41521-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Leroi N, Blacher S, Van Overmiere E, Van Ginderachter J, Lallemand F, Coucke P, Noel A, Martinive P. PO-1065: Impact of fractionated radiotherapy on tumor microenvironment. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41057-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Lallemand F, Leroi N, Balteau E, Bahri M, Noël A, Coucke P, Martinive P, Plenevaux A. EP-1526: Functional MRI for predicting metastatic spreading at the time of surgery after neoadjuvant radiotherapy. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41518-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Grari O, Dhouibi L, Lallemand F, Buron CC, Et Taouil A, Hihn JY. Effects of high frequency ultrasound irradiation on incorporation of SiO2 particles within polypyrrole films. Ultrason Sonochem 2015; 22:220-226. [PMID: 24835022 DOI: 10.1016/j.ultsonch.2014.04.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/07/2013] [Revised: 03/18/2014] [Accepted: 04/22/2014] [Indexed: 06/03/2023]
Abstract
This paper deals with the effect of ultrasound on polypyrrole/SiO2 composite film elaboration through various steps (particle dispersion, electrosynthesis). Experiments were carried out on stainless steel in phosphoric acid solution. An efficient method for dispersion of SiO2 particles prior to electropolymerization, based on low frequency irradiation (20kHz), was proposed. It was shown that mechanical effects of high frequency ultrasound (i.e. mass transfer improvement) led to enhancement of electropolymerization kinetics. Scanning electron microscopy imaging and glow discharge optical emission spectroscopy revealed localization of SiO2 particles in the outer region of the films as well as better incorporation of particles under high frequency ultrasound irradiation. Finally, anticorrosion behavior of formed films was investigated in sodium chloride solution by Open Circuit Potential and anodic polarization methods. The results showed that polypyrrole/SiO2 films elaborated under ultrasound irradiation exhibit the best protective performances.
Collapse
Affiliation(s)
- O Grari
- Unité de Recherche Mécanique-Energétique UR-11-ES-05 COPROMET ENIT BP 37, University of Tunis El-Manar, Belvedere, Tunis 1002, Tunisia; Institut UTINAM, UMR CNRS 6123, University of Bourgogne Franche-Comté, 30 Avenue de l'observatoire, 25009 Besançon Cedex, France
| | - L Dhouibi
- Unité de Recherche Mécanique-Energétique UR-11-ES-05 COPROMET ENIT BP 37, University of Tunis El-Manar, Belvedere, Tunis 1002, Tunisia
| | - F Lallemand
- Institut UTINAM, UMR CNRS 6123, University of Bourgogne Franche-Comté, 30 Avenue de l'observatoire, 25009 Besançon Cedex, France
| | - C C Buron
- Institut UTINAM, UMR CNRS 6123, University of Bourgogne Franche-Comté, 16 route de Gray, 25030 Besançon Cedex, France
| | - A Et Taouil
- Institut UTINAM, UMR CNRS 6123, University of Bourgogne Franche-Comté, 30 Avenue de l'observatoire, 25009 Besançon Cedex, France
| | - J Y Hihn
- Institut UTINAM, UMR CNRS 6123, University of Bourgogne Franche-Comté, 30 Avenue de l'observatoire, 25009 Besançon Cedex, France.
| |
Collapse
|
14
|
Ward RJ, Lallemand F, Dexter DT, De Witte P. SY39-4 * INFLUENCE OF SYSTEMIC INFLAMMATORY PROCESSES ON BRAIN IMMUNE SYSTEM. Alcohol Alcohol 2014. [DOI: 10.1093/alcalc/agu052.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Lallemand F, Lakosi F, Hustinx R, Withofs N, Meunier P, Tshibanda L, Jodogne S, Coucke P, Martinive P. [Functional imaging and radiotherapy]. Rev Med Liege 2014; 69 Suppl 1:20-28. [PMID: 24822301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Medical imaging plays a crucial role in the diagnosis, staging and therapeutic strategy of oncologic patients. The development of medical imaging over the last decade has allowed significant progresses in radiotherapy. Indeed, medical imaging is now considered the corner stone of radiotherapy. The main challenge for the radiation oncologist consists in the tumour identification with a view to irradiate the tumour at a curative dose while avoiding healthy tissues. To achieve these goals, the radiotherapist daily uses anatomical imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). Since several years now, the development of functional imaging such as positron emission tomography (PET) combined with CT or functional MRI has opened new perspectives in the management of oncologic diseases. Indeed, these imaging techniques offer new information on tumour metabolism that may be taken into account to plan the radiotherapy treatment. This article illustrates the different imaging techniques used in radiotherapy and the role of functional imaging for establishing new therapeutic strategies in radiation oncology.
Collapse
|
16
|
Haibe-Kains B, Desmedt C, Di Leo A, Azambuja E, Larsimont D, Selleslags J, Delaloge S, Duhem C, Kains J, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret J, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C. Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. Genom Data 2013; 1:7-10. [PMID: 26484051 PMCID: PMC4608867 DOI: 10.1016/j.gdata.2013.09.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Accepted: 09/12/2013] [Indexed: 11/19/2022]
Abstract
Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)–negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-alpha (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. Here we describe in details the contents and quality controls for the gene expression and clinical data associated with the study published by Desmedt and colleagues in the Journal of Clinical Oncology in 2011 (Desmedt et al., 2011). We also provide R code to easily access the data and perform the quality controls and basic analyses relevant to this dataset.
Collapse
Affiliation(s)
- B. Haibe-Kains
- Institut Jules Bordet, Brussels, Belgium
- Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium
- Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - C. Desmedt
- Institut Jules Bordet, Brussels, Belgium
| | | | | | | | | | | | - C. Duhem
- Centre Hospitalier du Luxembourg, Luxembourg
| | - J.P. Kains
- HIS—Site Etterbeek-Ixelles, Brussels, Belgium
| | - B. Carly
- Hopital Saint-Pierre, Brussels, Belgium
| | | | | | - G. Rouas
- Institut Jules Bordet, Brussels, Belgium
| | | | - V. Durbecq
- Institut Jules Bordet, Brussels, Belgium
| | - F. Cardoso
- Institut Jules Bordet, Brussels, Belgium
| | - R. Salgado
- Institut Jules Bordet, Brussels, Belgium
| | - R. Rovere
- Institut Jules Bordet, Brussels, Belgium
| | - G. Bontempi
- Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | - Y. Qi
- Institut Jules Bordet, Brussels, Belgium
| | - F. Symmans
- The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
| | - L. Pusztai
- Yale Cancer Center, Yale University, New Haven, CT, USA
| | - V. D'Hondt
- Institut Jules Bordet, Brussels, Belgium
| | | | - C. Sotiriou
- Institut Jules Bordet, Brussels, Belgium
- Corresponding author at: Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Bruxelles, Belgium. Tel.: +32 2 541 34 28; fax: +32 2 538 08 58.
| |
Collapse
|
17
|
Hoifodt-Lido H, Ericson M, Soderpalm B, Jonsson S, Adermark L, Ericson M, Soderpalm B, Ward R, Lallemand F, De Witte P, Korpi E, Adermark L, Soderpalm B, Burkhardt J. S05 * FUNCTIONAL IMPORTANCE OF INHIBITORY AMINO ACIDS IN THE EFFECTS OF ETHANOL. Alcohol Alcohol 2013. [DOI: 10.1093/alcalc/agt078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Zullino D, Achab S, Thorens G, Khan R, Manghi R, Khazaal Y, Lallemand F, Ward R, De Witte P, Caroli D, Rosa-Rizzotto E, Peraro L, Cocchio S, Baldo V, Simoncello I, Vendramin A, De Lazzari F, Lobello S, Van den Berg J, Hermes J, Van den Brink W, Blanken P, Kist N, Kok R. O6 * FREE ORAL COMMUNICATIONS 6: PSYCHOSOCIAL FACTORS AND ALCOHOL USE DISORDERS. Alcohol Alcohol 2013. [DOI: 10.1093/alcalc/agt112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Wiers R, Peeters M, Vollebergh W, Maurage P, Doallo S, Crego A, Parada M, Lopez-Caneda E, Corral M, Holguin SR, Cadaveira F, Campanella S, Petit G, Noel X, Saeremans M, Lallemand F, Ward R, De Witte P, Verbanck P. S23 * BINGE DRINKING IN YOUTHS: ARE INDUCED NEURO-COGNITIVE IMPAIRMENTS A FIRST STEP TOWARDS ALCOHOL DEPENDENCE? Alcohol Alcohol 2013. [DOI: 10.1093/alcalc/agt094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Hesselbrock M, Ward R, Lallemand F, Campanella S, Noel X, Verbank P, De Witte P, Walter H, Patek K, Maesato H, Hiromasa T, Itoh M, Kimura M, Matsushita S, Higuchi S. S30 * GENDER DIFFERENCES IN ALCOHOL DEPENDENCE II. Alcohol Alcohol 2013. [DOI: 10.1093/alcalc/agt108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Lakosi F, Lallemand F, Janvary L, Mievis C, Mathot M, Wonner M, Gulyban A, Coucke P, Seidel L, Vavassis P. EP-1300: Introduction of SagittiltÆ prone breast board into daily practice: From pre-clinical to first clinical experiences. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33606-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Lallemand F, Janvary ZL, Jansen N, Coucke P. [Cyberknife and benign pathologies]. Rev Med Liege 2011; 66:568-574. [PMID: 22216729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Conventional radiotherapy is known to be an effective treatment approach even for "benign" pathologies. However, this kind of treatment yields a high potential for side effects. The Cyberknife, a robotic stereotactic radiotherapy device, enables to offset a large proportion of the disadvantages encountered with conventional radiotherapy essentially through the high precision of dose administration and sparing of healthy tissues. Therefore, it seems to be a treatment of choice in the approach of some benign intracranial diseases. We review published data on indications and outcome of Cyberknife for intracranial "non-malignant" disease.
Collapse
|
23
|
Crichton R, Dexter DT, Ward RJ, Kalk N, Rabiner EA, Lingford-Hughes AR, Ward R, De Witte P, Lallemand F, Noel X, Campanella S, Verbank P, Crews F, Ward RJ. S14 * IDENTIFICATION OF NEUROINFLAMMATION IN THE BRAIN IN VIVO AND IN VITRO AND THERAPEUTIC STRATEGIES TO COMBAT ITS PROGRESSION * S14.1 * INFLAMMATORY PROCESSES IN NEURODEGENERATIVE DISEASES. Alcohol Alcohol 2011. [DOI: 10.1093/alcalc/agr104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Ward R, De Witte P, Lallemand F, Corte LD, Dexter DT, Bakalkin G, Yakovleva T, Pascual-Mora M, Balino P, Alfonso-Loeches S, Aragon C, Guerri C, Crews F. S06 * ROLE OF INNATE IMMUNE SYSTEM IN THE ETHANOL-INDUCED BRAIN DAMAGE, BEHAVIOURAL DYSFUNCTIONS AND ADDICTION * S06.1 * BINGE DRINKING INDUCES SIGNIFICANT CHANGES IN THE INNATE IMMUNE SYSTEM. Alcohol Alcohol 2011. [DOI: 10.1093/alcalc/agr091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Wrzosek M, Lukaszkiewicz J, Jakubczyk A, Wrzosek M, Matsumoto H, Wojnar M, Lee J, Lee B, Choi M, Chai Y, Choi I, Janu L, Rackova S, Horacek J, Sanchez-Catalan M, Hipolito L, Marti-Prats L, Orrico A, Zornoza T, Granero L, Polache A, Marti-Prats L, Sanchez-Catalan M, Orrico A, Hipolito L, Zornoza T, Polache A, Granero L, Sanchez-Catalan M, Marti-Prats L, Hipolito L, Orrico A, Zornoza T, Granero L, Polache A, Milivojevic V, Kranzler HR, Covault J, Glahn A, Wenzel C, Wilhelm J, Frieling H, Heberlein A, Bleich S, Hillemacher T, Colombo G, Lobina C, Carai MAM, Gessa G, Cacciaglia R, Loche A, Kuthcer E, Egorov A, Filatova E, Kulagina K, Filatova EV, Kuther E, Kulagina K, Egorov AY, Loi B, Lobina C, Maccioni P, Carai MAM, Gessa G, Colombo G, Ledesma J, Aragon CMG, Quoilin C, Didone V, Quertemont E, Kemppainen H, Raivio N, Kiianmaa K, Pascual-Mora M, Couto BRD, Minarro J, Guerri C, Alfonso-Loeches S, Pascual-Mora M, Urena-Peralta J, Pascual-Lucas M, Morillo MJ, Renau-Piqueras J, Guerri C, Marin M, Esteban-Pretel G, Ponsoda X, Romero A, Ballestin R, Lopez C, Megias L, Timoneda J, Molowni A, Renau-Piqueras J, Escrig MA, Aragon CMG, Raivio N, Tiraboschi E, Saarikoski ST, Castren E, Kiianmaa K, Tarragon E, Balino P, Aragon CM, Camarini R, Soares SL, Carrara-Nascimento PF, Godinho RO, Scavone C, Tarragon E, Aragon CM, Balino P, Aragon CM, Kanuri G, Kreusch F, Quertement E, Closon C, Didone V, Masson S, Seutin V, Quertemont E, Durazzo TC, Fryer SL, Hutchison KE, Mon A, Meyerhoff DJ, Nummi KP, Salaspuro M, Vakevainen S, Ukai W, Shirasaka T, Hashimoto E, Yoshinaga T, Kaneta H, Kigawa M, Igarashi T, Watanabe K, Tateno M, Ishii T, Saito T, Lallemand F, Ward RJ, De Witte P, Verbank P, Fiore M, Ceccanti M, Ceccanti M. POSTER SESSION 1: BASIC RESEARCH AND INTERNAL MEDICINE * BASIC RESEARCH * P01 * ASSOCIATION BETWEEN FOK I VITAMIN D RECEPTOR (VDR) GENE POLYMORPHISM AND IMPULSIVENESS IN ALCOHOL-DEPENDENT PATIENTS. Alcohol Alcohol 2011. [DOI: 10.1093/alcalc/agr117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Et Taouil A, Lallemand F, Hihn JY, Blondeau-Patissier V. Electrosynthesis and characterization of conducting polypyrrole elaborated under high frequency ultrasound irradiation. Ultrason Sonochem 2011; 18:907-910. [PMID: 21172737 DOI: 10.1016/j.ultsonch.2010.11.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2010] [Accepted: 11/26/2010] [Indexed: 05/30/2023]
Abstract
The effects of high frequency ultrasound (500kHz) on pyrrole electropolymerization in sodium perchlorate aqueous medium have been investigated. Cyclic voltametry studies showed that there is no influence on pyrrole oxidation potential. Scanning Electron Microscopy (SEM) imaging, and mechanical and optical profiling, revealed thinner, denser and more homogeneous surface structure for polypyrrole films elaborated under ultrasound irradiation. This is attributed to cavitation bubble asymmetric collapse close to the interface, which should induce changes in the nucleation-growth mechanism during the first polymerization stage. An increase of approximately 27% in doping level for sonicated films was revealed by X-ray Photoelectron Spectroscopy (XPS) analyses.
Collapse
Affiliation(s)
- A Et Taouil
- Institut UTINAM, UMR 6213 CNRS, Université de Franche-Comté, 30 Avenue de l'observatoire, 25009 Besançon, Cedex, France
| | | | | | | |
Collapse
|
27
|
Et Taouil A, Lallemand F, Hihn JY, Melot JM, Blondeau-Patissier V, Lakard B. Doping properties of PEDOT films electrosynthesized under high frequency ultrasound irradiation. Ultrason Sonochem 2011; 18:140-148. [PMID: 20493753 DOI: 10.1016/j.ultsonch.2010.04.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2009] [Revised: 04/06/2010] [Accepted: 04/08/2010] [Indexed: 05/29/2023]
Abstract
The present study presents the use of high frequency ultrasound (500 kHz, 25 W) for 3,4-ethylenedioxythiophene (EDOT) electropolymerization in aqueous medium in order to investigate its effects on conducting polymer properties. It was shown that mass transfer increases under ultrasound irradiation which improved electropolymerization and the comparison with experiments carried out at the same mass transfer level (4.6 × 10(-5) ms(-1)) puts in evidence that stirring effect is not the only phenomenon induced by ultrasound during electrodeposition. PEDOT films elaborated under ultrasonication present increased doping levels revealed by X-ray Photoelectron Spectroscopy (XPS) analysis, especially in the case of thick films (measured by mechanical probe), thanks to better incorporation of counter ions within polymer matrix as another consequence of mass transport improvement under ultrasound and probably film heating by wave absorption for the highest thicknesses. A dilation of the film under sonication leading to an increase in film thickness was also highlighted. Finally, a refining of the surface structure was also observed via SEM imaging.
Collapse
Affiliation(s)
- A Et Taouil
- Institut UTINAM, UMR 6213 CNRS, Université de Franche-Comté, 30 Avenue de l'observatoire, 25009 Besançon Cedex, France
| | | | | | | | | | | |
Collapse
|
28
|
Et Taouil A, Lallemand F, Hallez L, Hihn JY. Electropolymerization of pyrrole on oxidizable metal under high frequency ultrasound irradiation. Application of focused beam to a selective masking technique. Electrochim Acta 2010. [DOI: 10.1016/j.electacta.2010.07.083] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
29
|
Lallemand F, Ward RJ, De Witte P. The Influence of Chronic Nicotine Administration on Behavioural and Neurochemical Parameters in Male and Female Rats after Repeated Binge Drinking Exposure. Alcohol Alcohol 2009; 44:535-46. [DOI: 10.1093/alcalc/agp047] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics 2009; 2:37. [PMID: 19552798 PMCID: PMC2706265 DOI: 10.1186/1755-8794-2-37] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2009] [Accepted: 06/24/2009] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Within estrogen receptor-positive breast cancer (ER+ BC), the expression levels of proliferation-related genes can define two clinically distinct molecular subtypes. When treated with adjuvant tamoxifen, those ER+ BCs that are lowly proliferative have a good prognosis (luminal-A subtype), however the clinical outcome of those that are highly proliferative is poor (luminal-B subtype). METHODS To investigate the biological basis for these observations, gene set enrichment analysis (GSEA) was performed using microarray data from 246 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy. To create an in vitro model of growth factor (GF) signaling activation, MCF-7 cells were treated with heregulin (HRG), an HER3 ligand. RESULTS We found that a gene set linked to GF signaling was significantly enriched in the luminal-B tumors, despite only 10% of samples over-expressing HER2 by immunohistochemistry. To determine the biological significance of this observation, MCF-7 cells were treated with HRG. These cells displayed phosphorylation of HER2/3 and downstream ERK and S6. Treatment with HRG overcame tamoxifen-induced cell cycle arrest with higher S-phase fraction and increased anchorage independent colony formation. Gene expression profiles of MCF-7 cells treated with HRG confirmed enrichment of the GF signaling gene set and a similar proliferative signature observed in human ER+ BCs resistant to tamoxifen. CONCLUSION These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype.
Collapse
Affiliation(s)
- Sherene Loi
- Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Bouteille N, Driouch K, Hage PE, Sin S, Formstecher E, Camonis J, Lidereau R, Lallemand F. Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene 2009; 28:2569-80. [PMID: 19465938 DOI: 10.1038/onc.2009.120] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The WWOX gene encodes a candidate tumor suppressor protein (WWOX) implicated in a variety of human diseases such as cancer. To better understand the molecular mechanisms of WWOX action, we investigated novel partners of this protein. Using the two-hybrid system and a coimmunoprecipitation assay, we observed a physical association between WWOX and the Dishevelled protein (Dvl) family signaling elements involved in the Wnt/beta-catenin pathway. We found that enforced WWOX expression inhibited, and inhibition of endogenous WWOX expression stimulated the transcriptional activity of the Wnt/beta-catenin pathway. Inhibition of endogenous WWOX expression also enhanced the effect of Wnt-3a on beta-catenin stability. Moreover, we observed the sequestration of Dvl-2 wild type and Dvl-2NESm, a mutated form of Dvl-2 predominantly localized in the nucleus, in the cytoplasm compartment by WWOX. Our results indicate that WWOX is a novel inhibitor of the Wnt/beta-catenin pathway. WWOX would act, at least in part, by preventing the nuclear import of the Dvl proteins.
Collapse
Affiliation(s)
- N Bouteille
- Centre René Huguenin, FNCLCC, St-Cloud, France
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart MJ, Phillips WA, McArthur GA, Sotiriou C. Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.533] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
533 Background: The phosphathidylinositol-3-kinase (PI3K) signaling pathway is frequently deregulated in tumor biology and is an attractive target for cancer therapy. Our aim was to characterize the molecular and clinical outcome effects of PIK3CA mutations in breast cancer (BC). Methods: We analyzed 173 BC samples for PIK3CA mutations. Corresponding gene expression profiles were used to understand its effects on the PI3K pathway. We validated a PIK3CA-GS in 2 independent BC cohorts (n = 183) with known PIK3CA mutation status and evaluated its correlation with clinical outcome in 1748 BC samples stratified by treatment and subtype. Results: 26% of BCs had a PIK3CA mutation. Tumors with PIK3CA mutation demonstrated a distinct gene expression signature (p = 0.03 after 1000 perm). In 2 datasets it could discriminate PIK3CA mutation carriers from wild-type (ROC 0.68, 0.71, p = 0.001for both). However, the PIK3CA-GS was correlated with deactivation of the PI3K pathway probably through a negative feedback loop. This observation was supported by: 1) the PIK3CA-GS was significantly correlated with gene expression changes induced by PI3K inhibitors (Connectivity Map, Gene set enrichment analyses) and 2) the PIK3CA-GS was anti-correlated with a GS of PTEN loss (R = -0.3; Saal et al, 2007). Higher levels of the PIK3CA signature were observed in HER-2+ and estrogen receptor positive (ER+), luminal BC subtypes. Whilst there was no association with mutation status alone and prognosis, increasing expression of the PIK3CA-GS (suggesting deactivation) was significantly associated with better clinical outcome in both untreated (p = 0.04) and particularly ER+, luminal-B, tamoxifen only-treated (p = 0.004) BC. Multivariate analysis (HR: 0.4; 95%CI: 0.3–0.7; p = 0.002) confirmed that the PI3KCA-GS provided independent prognostic information. Conclusions: Paradoxically, the PIK3CA-GS correlates with inhibition of the PI3K pathway in ER+ BC and identifies a subgroup of luminal B BCs with a favorable outcome. The PIK3CA-GS may be a better indicator of PI3K pathway dysfunction than mutation status, potentially indicating patients who may benefit from combined endocrine therapy and PI3K inhibition. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Loi
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - B. Haibe-Kains
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - F. Lallemand
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - L. Pusztai
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - A. Bardelli
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - C. Gillett
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - P. Ellis
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - M. J. Piccart-Gebhart
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - W. A. Phillips
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - G. A. McArthur
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| | - C. Sotiriou
- Institut Jules Bordet, Brussels, Belgium; M. D. Anderson Cancer Center, Houston, TX; Institute for Cancer Research and Treatment, Torino, Italy; Guy's Hospital, London, United Kingdom; Peter MacCallum Cancer Center, Melbourne, Australia
| |
Collapse
|
33
|
Lakard B, Ploux L, Anselme K, Lallemand F, Lakard S, Nardin M, Hihn JY. Effect of ultrasounds on the electrochemical synthesis of polypyrrole, application to the adhesion and growth of biological cells. Bioelectrochemistry 2009; 75:148-57. [PMID: 19359224 DOI: 10.1016/j.bioelechem.2009.03.010] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2008] [Revised: 03/13/2009] [Accepted: 03/14/2009] [Indexed: 11/17/2022]
Abstract
In this study, a new way to synthesize polypyrrole films is presented. This original way consists in the electropolymerization of polypyrrole under high frequency ultrasonic irradiation on conductive fluorine-doped tin oxide surfaces. The polypyrrole films obtained are then compared, in terms of chemical structure and morphology, to polypyrrole films synthesized by standard electrochemical methodology. Next, these polymer films are tested as an alternative to biomaterials that are commonly used as cell culture substrates. Thus, the adhesion and growth of osteoblastics cells and microbial cells on polymer-modified surfaces are investigated by using qualitative observation and quantitative tests. These studies proved the non-toxicity of the polymer films for osteoblastic and microbial cells but also a different behaviour of osteoblastic cells and microbial cells with polypyrrole films.
Collapse
Affiliation(s)
- B Lakard
- Institut UTINAM, UMR-CNRS 6213, Université de Franche-Comté, 16 route de Gray, 25030 Besançon Cedex, France.
| | | | | | | | | | | | | |
Collapse
|
34
|
Roux N, Freguin-Bouilland C, Brakenheilm E, Lallemand F, Thuillez C, Plissonnier D. N010 Prévention du rejet vasculaire par mobilisation de cellules progénitrices endothéliales. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72439-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
35
|
Debunne M, Rivault F, Lallemand F, Henry JP, Renet S, Noack P, Massonneau M, Thuillez C, Richard V. M002 Molecular imaging of cardiac fibrosis with a new fluorescent probes directed against MMPs. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72427-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Leveque S, Roux N, Freguin-Bouilland C, Brakenheilm E, Lallemand F, Thuillez C, Plissonnier D. A015 Étude de la cinétique de SDF1, VEGF et MCP1 dans le rejet vasculaire : modèle de greffe aortique chez la souris. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72148-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Fang Y, Bauer F, Mulder P, Brakenhielm E, Lallemand F, Gluais P, Roussel J, Thuillez C. H031 Short-term heart rate reduction induced by ivabradine administered to rats with well-established heart failure improves cardiac function, augments neo-angiogenesis and reduces myocardial hypoxia. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72330-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
38
|
Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens M, Smeets A, Lallemand F, Piccart M, Gelber R, Sotiriou C. The Genomic Grade Index (GGI) – a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70797-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
39
|
Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus N, Piccart MJ, Speed T, McArthur GA. Investigating tamoxifen resistance in the luminal B estrogen receptor positive breast cancer subtype: Tailoring treatment in hormone responsive breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10603] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10603 Background: We recently reported that the two estrogen receptor (ER) positive breast cancer (BC) molecular subtypes can be defined by their expression of proliferation genes using a gene expression index (GGI): the luminal A and B subtypes have low and high levels respectively (J Clin Onc, in press). When treated with adjuvant tamoxifen, luminal A tumors have a good prognosis, however the clinical outcome of the luminal B subtype was poor. This study aimed to explain the biological basis for these observations using global gene expression profiling and an in vitro model of ER+ BC. Methods: 246 ER+ BC samples from women treated with adjuvant tamoxifen monotherapy were analyzed with affymetrix gene expression arrays and evaluated using gene set enrichment analysis (GSEA). ER+ MCF-7 BC cells (control) treated with tamoxifen (TAM) and heregulin (HRG) were used to investigate molecular pathways identified using GSEA. Results: We found that a gene set suggesting ERBB2 pathway activation was significantly enriched in the luminal B subtype (p=0.02). Only 10% of samples overexpressed HER2 by immunohistochemistry, suggesting that activation of HER2 signaling pathways is independent of HER2 overexpression and may contribute to TAM resistance in this subtype. To validate this hypothesis, MCF-7 cell-lines were treated with HRG (HRG-MCF7) to create a model of ERBB2 pathway activation. HRG-MCF7 cells displayed phosphorylation of HER2/3 without HER2 overexpression. Treatment with HRG overcame TAM induced cell cycle arrest with higher S-phase fraction (p<0.01) and increased anchorage- independent colony formation (p<0.01). Gene expression profiling confirmed significant enrichment of the ERBB2 gene set (p<0.01) and higher GGI levels (p=0.02) in HRG-MCF7 cells compared with control. Conclusions: HRG-MCF7 cells may be useful as an in vitro model of the TAM resistant luminal B subtype. In this group, targeting activated HER2 signaling may be a helpful treatment strategy despite the lack of HER2 overexpression. Our data suggests that agents like lapatinib may be effective only in the luminal B and not the luminal A tumors, demonstrating the importance of stratifying by subtype in future clinical trials of ER+ disease. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Loi
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| | - C. Sotiriou
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| | - B. Haibe-Kains
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| | - F. Lallemand
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| | - N. Conus
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| | - M. J. Piccart
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| | - T. Speed
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| | - G. A. McArthur
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; Walter and Eliza Hall Institute, Melbourne, Australia
| |
Collapse
|
40
|
Lallemand F, Varesio E, Felt-Baeyens O, Bossy L, Hopfgartner G, Gurny R. Biological conversion of a water-soluble prodrug of cyclosporine A. Eur J Pharm Biopharm 2007; 67:555-61. [PMID: 17475453 DOI: 10.1016/j.ejpb.2007.03.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2006] [Revised: 02/22/2007] [Accepted: 03/07/2007] [Indexed: 11/23/2022]
Abstract
UNIL088 is a water-soluble prodrug of cyclosporine A (CsA) designed for topical ocular delivery. The pro-moiety is grafted via an ester function to CsA and the solubilizing group is a phosphate ion. The aim of this study was to elucidate the conversion mechanisms by which UNIL088 generates CsA. UNIL088 was incubated in rabbit tears at physiological temperature to study its enzymatic and chemical conversion, respectively. Metabolites and intermediates were identified using a quadrupole-time of flight (QqTOF) mass spectrometer, which allowed biotransformation pathways to be deduced. Conversion is activated by the chemical or enzymatic hydrolysis of the terminal ester function of the pro-moiety, leading to the phospho-serine-sarcosine-cyclosporine A that spontaneously converts into CsA. In addition to the main biotransformation pathway, a secondary reaction involved hydrolysis of the phosphate ester group of the pro-moiety, probably by phosphatases present in tears.
Collapse
Affiliation(s)
- F Lallemand
- Department of Pharmaceutics and Biopharmaceutics, University of Geneva, University of Lausanne, Geneva, Switzerland
| | | | | | | | | | | |
Collapse
|
41
|
Lallemand F, Auguste D, Amato C, Hevesi L, Delhalle J, Mekhalif Z. Electrochemical synthesis and characterization of N-substituted polypyrrole derivatives on nickel. Electrochim Acta 2007. [DOI: 10.1016/j.electacta.2006.12.010] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema ADR, Nuijen B, Nol A, Beijnen JH, Schellens JHM. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 2006; 95:729-34. [PMID: 16926835 PMCID: PMC2360510 DOI: 10.1038/sj.bjc.6603312] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
To explore the parmacokinetics, safety and tolerability of paclitaxel after oral administration of SMEOF#3, a novel Self-Microemulsifying Oily Formulation, in combination with cyclosporin A (CsA) in patients with advanced cancer. Seven patients were enrolled and randomly assigned to receive oral paclitaxel (SMEOF#3) 160 mg+CsA 700 mg on day 1, followed by oral paclitaxel (Taxol®) 160 mg+CsA 700 mg on day 8 (group I) or vice versa (group II). Patients received paclitaxel (Taxol®) 160 mg as 3-h infusion on day 15. The median (range) area under the plasma concentration–time curve of paclitaxel was 2.06 (1.15–3.47) μg h ml−1 and 1.97 (0.58–3.22) μg h ml−1 after oral administration of SMEOF#3 and Taxol®, respectively, and 4.69 (3.90–6.09) μg h ml−1 after intravenous Taxol®. Oral SMEOF#3 resulted in a lower median Tmax of 2.0 (0.5–2.0) h than orally applied Taxol® (Tmax=4.0 (0.8–6.1) h, P=0.02). The median apparent bioavailability of paclitaxel was 40 (19–83)% and 55 (9–70)% for the oral SMEOF#3 and oral Taxol® formulation, respectively. Oral paclitaxel administered as SMEOF#3 or Taxol® was safe and well tolerated by the patients. Remarkably, the SMEOF#3 formulation resulted in a significantly lower Tmax than orally applied Taxol®, probably due to the excipients in the SMEOF#3 formulation resulting in a higher absorption rate of paclitaxel.
Collapse
Affiliation(s)
- S A Veltkamp
- Division of Experimental Therapy, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Lallemand F, Furrer P, Felt-Baeyens O, Gex-Fabry M, Dumont JM, Besseghir K, Gurny R. A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics. Int J Pharm 2005; 295:7-14. [PMID: 15847987 DOI: 10.1016/j.ijpharm.2004.12.015] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2004] [Accepted: 12/10/2004] [Indexed: 10/25/2022]
Abstract
The purpose of this study is to demonstrate that a novel water-soluble prodrug of cyclosporine A (CsA) intended for topical ocular administration, does not induce eye irritation in a rabbit model and is able to generate therapeutic concentrations of CsA in the precorneal area immediately after administration. The eye irritancy of the prodrug and CsA control solution was assessed by the Draize test and by confocal laser ophthalmoscopy (CLSO). Residence time and tear concentrations of prodrug and CsA in the rabbit eye were assessed by HPLC. The Draize test showed an excellent tolerance for the prodrug solution while the reference CsA oil solution induced lachrymation and irritation. The CLSO-measured corneal lesions, subsequent to treatment with the prodrug and reference solutions, were 3% and 9%, respectively. The prodrug transformed rapidly, leading to relatively stable CsA concentrations in tears with a maximal concentration of 94 microg ml(-1) over the observation period. This study demonstrated that the prodrug solution was well tolerated and that clinically significant CsA tear concentrations were achieved. UNIL088 is a promising molecule in the treatment of immune-related disorders of the eye.
Collapse
Affiliation(s)
- F Lallemand
- Laboratory of Pharmaceutical Technology and Biopharmaceutics, School of Pharmacy, University of Geneva, 1211 Geneva 4, Switzerland
| | | | | | | | | | | | | |
Collapse
|
44
|
Lallemand F, Felt-Baeyens O, Rudaz S, Hamel AR, Hubler F, Wenger R, Mutter M, Besseghir K, Gurny R. Conversion of cyclosporine A prodrugs in human tears vs rabbits tears. Eur J Pharm Biopharm 2005; 59:51-6. [PMID: 15567301 DOI: 10.1016/j.ejpb.2004.07.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2004] [Accepted: 07/01/2004] [Indexed: 11/28/2022]
Abstract
The aim of this study was to evaluate the rate and mechanism of conversion of two water-soluble prodrugs of cyclosporine A (CsA) intended for topical delivery to the eye. The new molecules were designed according to the double prodrug concept: a solubilizing moiety was grafted onto CsA via an ester function, which could be hydrolysed via a two-step process (enzymatic and chemical). Prodrug solutions were prepared extemporaneously in an isotonic and neutral aqueous medium compatible with ophthalmic use. The rates of conversion into the parent molecule were determined by incubating the prodrugs in fresh rabbit or human tears or in a phosphate buffer solution (PBS) at pH 7.4. Both prodrugs were converted into CsA within the first minute in the presence of rabbit tears with rate constants of k=5.9x10(-3)min(-1) and k=3.8x10(-3)min(-1), respectively, for UNIL088 and UNIL089, whereas chemical conversion in PBS was negligible (k=0.5x10(-3)min(-1) for both molecules). Incubation of UNIL088 in human tears showed a significantly high conversion rate. It is concluded that the developed double prodrugs underwent a bioconversion in physiological media and thus represent promising candidates for topical delivery of CsA to the eye.
Collapse
Affiliation(s)
- F Lallemand
- Laboratory of Pharmaceutical Technology and Biopharmaceutics, School of Pharmacy, University of Geneva, Geneva, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Lacroix M, Haibe-Kains B, Hennuy B, Laes JF, Lallemand F, Gonze I, Cardoso F, Piccart M, Leclercq G, Sotiriou C. Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. Oncol Rep 2005; 12:701-7. [PMID: 15375488 DOI: 10.3892/or.12.4.701] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have examined the effects of the protein kinase C (PKC)-activator phorbol 12-myristate 13-acetate (PMA) on gene expression in two breast cancer cell (BCC) lines exhibiting highly different phenotypes. These are the estrogen receptor alpha (ERalpha)-positive, weakly invasive, luminal epithelial-like MCF-7 and the ERalpha-negative, highly invasive, fibroblast-like MDA-MB-231. They express constitutively low and high PKC activities, respectively. After a 24-h exposition to 100 nM PMA, the number of genes showing an altered expression at the 2-fold change level was much higher in MCF-7 (n=435) than in MDA-MB-231 (n=18) BCC. Four of these genes, namely CDC2, CENPA, NR4A1 and MMP10, were altered in the same way in both cell lines. Two genes were regulated in an opposite way: ID1 and EVA1. Many of the genes down-regulated in MCF-7 BCC appeared to be preferentially expressed in the G1, S, and/or G2 phases of the cell cycle. The ERalpha gene, ESR1, and other genes associated to the ERalpha-positive, luminal epithelial-like BCC phenotype were down-regulated, while a series of genes related to a more aggressive, fibroblast-like BCC phenotype were up-regulated. Other altered genes were notably linked to cell architecture, supporting profound effects of PMA on cell morphology and motility, as well as on the interactions between BCC and their neighboring proteins. Of note, all the modulated genes involved in proteolysis and its control were up-regulated. In summary, PMA effects suggest that PKC activation may induce, to some extent, a more fibroblast-like phenotype in the ERalpha-positive, luminal epithelial-like MCF-7 BCC, and significantly modulate the interactions of these cells with their environment.
Collapse
Affiliation(s)
- M Lacroix
- Laboratoire Jean-Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Free University of Brussels, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bourges J, Agla K, Lallemand F, Halhal M, Bejjani R, Dumont J, Besseghir K, Renard G, Benezra D, Behar-Cohen F. 216 Modulation du rejet aigu de greffe par une « prodrug » de ciclosporine A administrée par voie topique. J Fr Ophtalmol 2005. [DOI: 10.1016/s0181-5512(05)74612-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Abstract
AIMS Previous studies have shown that CB(1) cannabinoid receptors are involved in the behavioural effects induced by chronic ethanol administration in Wistar rats by using SR 141716, a CB(1) cannabinoid receptor antagonist. These studies have now been extended to investigate the effect of acute and chronic alcoholization on blood ethanol concentration (BEC) and ethanol preference in CB(1) knockout (-/-) mice. METHODS BEC was monitored for a period of 8 h in both CB(1)(-/-) male mice and CB(1) male wild-type (+/+) mice, which had received an acute i.p. injection of ethanol in 1, 3 or 5 g/kg doses. Ethanol preference was assayed in both groups of male mice in non-forced ethanol administration and forced chronic pulmonary alcohol administration for 14 and 39 days, respectively. RESULTS After an acute intraperitoneal ethanol injection of 5 g/kg, CB(1)(-/-) mice showed a significant higher BEC during the ethanol elimination stage than the CB(1)(+/+) mice. However, those in the 1 and 3 g/kg groups showed no significant difference. A 2-3 fold increase in BEC was observed in CB(1)(-/-) mice on days 10 and 11 after commencement of forced chronic pulmonary alcoholization in comparison with CB(1)(+/+) mice, although comparable BEC values were assayed in both groups on day 12. In addition, these CB(1)(-/-) mice showed a significantly lower preference for ethanol than CB(1)(+/+) mice. CONCLUSIONS The studies on CB(1)(-/-) and CB(1)(+/+) mice have clearly confirmed the involvement of CB(1) receptor on ethanol induced behavioural effects and also revealed that CB(1) receptors may be implicated in ethanol absorption/distribution, particularly after administration of high ethanol doses.
Collapse
Affiliation(s)
- F Lallemand
- Biologie du Comportement, Université Catholique de Louvain, 1 Place Croix du Sud, 1348 Louvain-la-Neuve, Belgium
| | | |
Collapse
|
48
|
Abstract
Systemic administration of cyclosporine A (CsA) is commonly used in the treatment of local ophthalmic conditions involving cytokines, such as corneal graft rejection, autoimmune uveitis and dry eye syndrome. Local administration is expected to avoid the various side effects associated with systemic delivery. However, the currently available systems using oils to deliver CsA topically are poorly tolerated and provide a low bioavailability. These difficulties may be overcome through formulations aimed at improving CsA water solubility (e.g. cyclodextrins), or those designed to facilitate tissue drug penetration using penetration enhancers. The use of colloidal carriers (micelles, emulsions, liposomes and nanoparticles) as well as the approach using hydrosoluble prodrugs of CsA have shown promising results. Solid devices such as shields and particles of collagen have been investigated to enhance retention time on the eye surface. Some of these topical formulations have shown efficacy in the treatment of extraocular diseases but were inefficient at reaching intraocular targets. Microspheres, implants and liposomes have been developed to be directly administered subconjunctivally or intravitreally in order to enhance CsA concentration in the vitreous. Although progress has been made, there is still room for improvement in CsA ocular application, as none of these formulations is ideal.
Collapse
Affiliation(s)
- F Lallemand
- School of Pharmacy, University of Geneva, Geneva, Switzerland
| | | | | | | | | |
Collapse
|
49
|
Lallemand F, De Witte P. Taurine concentration in the brain and in the plasma following intraperitoneal injections. Amino Acids 2004; 26:111-6. [PMID: 15042438 DOI: 10.1007/s00726-003-0058-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2003] [Accepted: 10/27/2003] [Indexed: 10/26/2022]
Abstract
Summary. The effect of different taurine doses (0.050, 0.125, 0.250, 0.500 and 1.000 g/kg) administered intraperitoneally to Wistar rats was studied in both the plasma and the hippocampal microdialysate content. The samples were analyzed by reverse phased HPLC for the microdialysate samples and by HPLC with ion-exchange post-column derivatization (ninhydrin) for the plasma samples. In both plasma and microdialysate, we observed a dose dependent increase of taurine concentration. The AUC curves obtained from both microdialysate and plasma samples showed that the increase of taurine concentrations were linear. The mean ratio between AUC's microdialysate and plasma was 1.63+/-0.21 showing thus an unbalance between plasma and brain taurine content; a mechanism which enhance taurine transfer from the plasma to the brain was assumed.
Collapse
Affiliation(s)
- F Lallemand
- Biologie du Comportement, Université catholique de Louvain, 1 Croix du Sud, 1348 Louvain-la-Neuve, Belgium
| | | |
Collapse
|
50
|
Lallemand F, Ricq L, Berçot P, Pagetti J. Effects of the structure of organic additives in the electrochemical preparation and characterization of CoFe film. Electrochim Acta 2002. [DOI: 10.1016/s0013-4686(02)00369-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|